获取演示
Now livetag icon
What will define the 2026 holiday season? 🔎 See how shoppers are deciding. Download the reportbanner icon
Invicro

三月 2026

三月 2026的Invicro市场份额分析

Perceptive, the industry’s most trusted provider of preclinical to late-phase imaging solutions, Randomization & Trial Supply Management(RTSM)
成立年份2008
员工201 - 500
年营收$100M - $200M
invicro.com
Invicro
Invicro(包含公司地区分支机构)
  • invicro.com
    invicro.com
查看更多网站流量和参与度信息

Invicro收入截至 三月 2026为 100M - 200M

Invicro主要域名产生的收入

3 年中Invicro主要域名的收入

Invicro主要域名的收入


Invicro热门域名的总访问量

了解Invicro市场份额和潜在市场覆盖范围。

过去 3 个月的总访问量

子公司明细

Invicro热门域名的平均访问时长

分析Invicro参与度指标。

过去 3 个月的平均访问时长

子公司明细

Invicro热门域名的平均页面浏览量

了解Invicro如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。

过去 3 个月的平均页面浏览量

子公司明细

想要获取更深入的流量洞见?

过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。



Invicro 采用的主要技术

这些是排名前 Invicro 的顶级域名所使用的网站技术(按行业分列)

付费广告 (7)

DoubleClick

DoubleClick

小部件 (4)

内容管理系统 (3)

WordPress

WordPress

营销 (3)

Google Marketing Platform

Google Marketing Platform

更多技术

11

查看全部

准备好发现优质潜在客户了吗?

借助 Similarweb 销售情报解决方案,确定任意网站使用了哪些技术来设计完美的销售宣传,并缩短销售周期。


Invicro 的新闻与信号

借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。

新闻Calyx acquires Invicro.Nottingham-based Calyx, a provider of medical imaging services and IRT/RTSM (Interactive Response Technology/Randomised Trial Supply Management) to drug developers, is acquiring 100% of Invicro, a next-generation quantitative imaging biomarker company and development partner to pharma sponsors, from its current owner, REALM IDx, a US-based healthcare company pioneering the field of integrated diagnostics,
新闻Invicro partners with Akoya Biosciences, Inc..“Invicro is excited to partner with Akoya for early access to the new PhenoCode Signature Panels, which will simplify approaches to create rich, contextual biomarker data and help us accelerate the discovery and validation of immunotherapy biomarkers,” said Joseph Krueger, PhD, Vice President of Invicro’s Advanced Pathology Services.
新闻ImaginAb, Inc. partnered with Invicro on May 12th '22.ImaginAb Inc., a market-leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), today announced a new agreement with Invicro LLC, a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to supply clinical doses of ImaginAb's investigational CD8 ImmunoPET agent (zirconium Zr 89 crefmirlimab berdoxam) for use in clinical trials as part of Invicro's global core lab imaging service.

查看 Invicro 的所有信号

让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。